- Home
- MMU vs LENZ Comparison
MMU vs LENZ Comparison
Compare MMU & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMU | LENZ |
|---|---|---|
| Founded | 1992 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 567.5M | 609.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MMU | LENZ |
|---|---|---|
| Price | $10.62 | $15.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $56.25 |
| AVG Volume (30 Days) | 170.7K | ★ 1.2M |
| Earning Date | 01-01-0001 | 03-18-2026 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $203.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.60 | $14.43 |
| 52 Week High | $10.45 | $50.40 |
Technical Indicators
Market Signals| Indicator | MMU | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 36.47 |
| Support Level | $10.29 | $14.87 |
| Resistance Level | $10.62 | $21.80 |
| Average True Range (ATR) | 0.08 | 1.60 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 95.59 | 10.02 |
Price Performance
Historical ComparisonAbout MMU Western Asset Managed Municipals Fund Inc.
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. The fund predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations).
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.